Figure 9
AFM representative images showing the morphology and roughness of human erythrocytes. (A) Morphology of untreated erythrocytes (control group) and after exposure to the Ocellatin-K1(1–16) (B,D,F at 250, 500, and 1000 µg/mL, respectively) and to the Ocellatin-K1(1–21) (C,E,G at 250, 500, and 1000 µg/mL, respectively). (H) Average roughness of human erythrocytes untreated (control) and treated with Ocellatin-K1(1–16) and Ocellatin-K1(1–21) at concentrations ranging from 250 to 1000 µg/mL. *p < 0.0001 vs. control group using ANOVA and t-test. Abbreviations: K1(1–16): Ocellatin-K1(1–16); K1(1–21): Ocellatin-K1(1–21).
